About the Conference

The 9th World Conference on Pharmaceutical Science and Drug Manufacturing endeavors to render a unique platform for researchers, specialists, academics, pharmaceutical industry authorities and associated fields of global community pharmaceutical healthcare to trade and distribute their phenomenal experiences and critical knowledge and innovations are being made in the pharmaceutical sciences. The scientific sessions of the conference (which have been carefully and meticulously planned to offer delegates the most knowledge and expertise), will highlight the necessity to focus on modifications in some of the principal domains of pharmaceutical technology, drug formulation and analytical techniques, phytochemical and pharmacological sciences, pharmaceutical examination, as well as the pharmaceutical industry and the healthcare industry, in general, together with all related health care sectors.

Objective of Pharma Conference 2021

All key stakeholders and partners who are in support of the 9th World Conference on Pharmaceutical Science and Drug Manufacturing to held on the 28th - 29th July, 2021 in the beautiful city of Dubai, United Arab Emirates will convene a high-level forum on the improvement of access to essential medicines as well as manufacturing globally.

The event will focus on setting clear priorities for specific coordinated and effective actions, as well as multi-employer platforms with the support and determination of high-level decision-makers to realize the vision of leaders of the Pharmaceuticals industry.

The overall objective of the forum is to promote tangible efforts that will advance access to affordable primary medications and catalyze global production by mobilizing high-level executive commitments and viable solutions.

This conference has been designed to examine the evidence regarding constraints, opportunities and examples of good practice within the Pharma industry and also closely review a wide range of issues to manufacturing such as the harmonization of regulatory protocols, research and development, production, quality control, distribution, diagnostics and diagnostics and health care capacity development as well as incentives to stimulate progressive global healthcare initiatives and other worthy health systems initiatives.